News stories about Sequenom (NASDAQ:SQNM) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sequenom earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 96 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the near future.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Extremely Likely to Affect Sequenom (SQNM) Share Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-extremely-likely-to-affect-sequenom-sqnm-share-price/1390118.html.

Sequenom Company Profile

Sequenom, Inc is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina.

Receive News & Ratings for Sequenom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sequenom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.